中文
Press Release
Press Release
2023 2022 2021 2020 2019 2018 2017
Mar 16, 2023
Mabwell's Clinical Trial Application for 9MW3811 Accepted by NMPA

➞
Mar 13, 2023
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011

➞
Mar 03, 2023
Mabwell's Clinical Trial Application for 9MW3911 Injection - An Innovative Drug, Accepted by NMPA

➞
Feb 27, 2023
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

➞
Feb 05, 2023
Accelerating Development of Mabwell's ADC Plateform: Clinical Trial Application for an Innovative Drug (9MW2921) Accepted by NMPA

➞
Jan 20, 2023
$412.5 Million Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

➞
Jan 03, 2023
Mabwell Announces the NMPA Approval of 9MW3011 (FIC) for IND

➞